National

Ongoing

- EPIRNATHER - PN-IV-P1-PCE-2023 - Advanced therapeutic strategy in atherosclerosis based on epitranscriptomic reprogramming.

- INNACOL- PN-IV—P7-.7.1.-PED 2024 - Innovative substitutes with three-dimensional structure and antimicrobial activity based on collagen for craniofacial reconstruction .

- ReGenTACol - PN-IV-P7-7.1-PED- Development of an innovative collagen-based matrix with improved properties, intended for encapsulating pancreatic islets for transplantation

- SEARCH -VASC- PN-IV-P6-6.1-CoEx-2024-0029 - Center of Excellence in Advanced Translational Research in Cardiovascular and Neurovascular Diseases

- DIATARGET - PN-IV-P2-2.1-TE-2023-1203 - Exploring the role of long non-coding RNAs as potential targets in diabetes-associated aortic valve disease

Completed

• 2A PN-III-P1-1.1-TE-2019-2024 Contract No.: 104/08.09.2020 UEFISCDI Project title: Apolipoprotein A-II derived peptides with anti-atherosclerotic potential
• CARDIOCRISPR PN-III-P2-2.1-PED-2021-1929 Contract No.: PED-640/2022. Project title: Experimental demonstration of an innovative biotechnology using CRISPR/dCas9 transcriptional activation to improve HDL function as a therapy for cardiovascular diseases
• E4-HDLResearch grant GAR2023; Project code 82
• INTERSECTResearch grant GAR2023 Project code 83
• FIBROTHER Grant No.: PN-III-P1-1.1-TE-2021-1344, Contract No .: 149/2022, implementation period : 09/06/2022-07/06/2024
• NEPHRODIAB Project code:PN-III-P1-1.1-TE-2021-0180; Contract No: TE 141/2022; Project title: Therapeutic strategy in diabetic nephropathy based on targeting epigenetic mechanisms involved in renal failure and metabolic memory
• OXIGENEDIT PN-III-P4-PCE-2021-0831, Contract No .: PCE-90/2022, Project title: Boosting endogenous anti-oxidant enzymes by CRISPR/Cas9-based gene editing, an innovative approach for complementary therapy in metabolic disorders
• PRE-GDM : PN-III-P1-1.1-TE-2021-1161 (TE154) – Project title : Blood circulating molecular chaperons - potential markers for gestational diabetes evolution; a proteomic analysis
• DIAMARK PN-III-P4-PCE-2021-1344 (PCE114) – Project title : Molecular markers for prediction of evolution and prognosis in diabetic foot management
• VALDYSIGN Project code : PN-III-P1-1.1-PD-2021-0498 ; Contract No .: PD 35/2022 ; Title of the project : Impact glucose ENHANCED in interplay from cell ENDOTHELIAL valvular and monocyte : signature molecular and role in dysfunction valvular
• OXI-SCENARIO PN-III-P1-1.1-PD-2016-1903: Interference with hypoxia-signaling pathways in mesenchymal stem cells prior to transplantation as a strategy to enhance myocardial recovery post infarction
• RNATHER PN-III-P1-1.1-TE-2016-0851; Contract No .: 51/2018. Project Title : Preclinical strategy to reduce vascular inflammation and oxidative stress by targeting novel non-coding RNA pathways in atherosclerosis
• THERADIAB PN-III-P2-2.1-PED-2019-2512 ; Contract No. : 265PED/2020; Project title : Innovative triterpenes-based pharmacological strategy for the treatment of diabetes-associated micro- and macrovascular disorders – preclinical study
• VAPO Project: PN-III-P2-2.1-PED-2019-4574 (267PED) – Project title : Growth demonstration potential ANTI atherosclerotic activity of apolipoprotein E targeting activated endothelium, by Demonstration of enhanced antiatherosclerotic potential of apolipoprotein E targeting activated endothelium by fusion with VCAM-1 binding peptide
• INNATE-ME PN-III-P4-ID-PCCF-2016-0172 Contract No .: 05/18.07.2018. Project title : Targeting innate immune mechanisms to improve risk stratification and to identify future therapeutic options inmyocardial infarction
• PROSKIN PN-III-P1-1.1-TE-2016-1592, Contract No.: 3/2018 . Project title : Mesenchymal stromal cells contribution to the reepithelialization process of the biomimetic skin cultures by differentiation and paracrine factors.
• NANOLIFE PN-III-P1-1.2-PCCDI-2017-0749, Contract No .: 45/2018, Implementation period : 16.04.2018-30.09.2020. Project title : Bioactive nanostructures for innovative therapeutic strategies
• NanoApoE PN-III-P1-1.1-PD-2016-1942. Project title: Evaluation of the therapeutic potential of non-viral apolipoprotein E gene transfer to limit progression of atherosclerosis
• NANOGINROSA PN-III-P2-2.1-PED-2019-3552 / Contract No.: 270 PED/2020 – Project title : Development of innovative nanophytosomes designed for non-invasive administration with increased bioavailability of biologically active compounds with antioxidant and immunostimulatory properties
• NANORES PN-III-P4-ID-PCE-2020-2465 / Contract No .: PCE68/ 2021. Project title : Targeted therapy based on biomimetic nanocarriers for resolution of inflammation in atherosclerosis
• NAMIGEL PN-III-P2-2.1-PED-2019-4906; Contract No .: PED 534/23.10.2020; Project Title: Development and validation of a native cardiac hydrogel for myocardial repair post infarction
• INTERA PN-III-P1-1.2-PCCDI-2017-0697/ Contract No .: 13PCCDI ⁄ 2018. Project Title : Smart Therapies for Non- Communicable Diseases, Based on Person Controlled Release of Pharmacological Decomposition from Cell Encapsulated After Genetic Manipulation or Vectorized Bionanoparticles
• IMPLEXIA PN-III-P1-1.1-TE-2019-0811/ Contract No .: TE 97 /2020 / Project Title : Modulation of T-cell immunity by each platelet and microvesicle platelet aggregation in experimentally induced atherosclerosis ; the role of microRNA-142-3p
• BIOVEA PN-III-P1-1.2-PCCDI-2017-0527/ Contract No. : 83 PCCDI/2018 Project Title : Development of BIOnanotechnologies based on extracellular Vesicles for early diagnosis, prognosis and therapy of Atherosclerotic disease
• EPITERAMI PN-III-P2-2.1-PED-2019-1897/ Contract No.: 257PED/2020 Project title: Validation of a plasma measurement protocol of a panel of epigenetic markers ( microRNA ) for prognosis of evolution and personalization of therapy in patients after acute myocardial infarction
• ERASER PN-III-P4-ID-PCE-2020-1898, Contract No.: PCE 81/2021. Project title: Advanced therapeutic strategy in atherosclerosis based on epigenetic reprogramming
• FasTrap Project PN-III-P4-PCE-2021-1755 (PCE124) – Project title: A novel anti-atherosclerotic chimeric protein for prevention the inflammatory cells infiltration in the atheromatous plaque

EPITHER PN-III-P4-ID-PCE-2016-0665. Contract No .: 69/2017. Project Title : Novel epigenetic pathways to induce anti-inflammatory macrophages as potential therapeutic targets in atherosclerosis.

• Ep-Angio Title: Dynamics of the endothelial junctional proteins in HMGB1-induced angiogenesis; Clinical implications(Contract PD 138/2018) - 2018-2020
• ECHOTHERA PN-III-P2-2.1-PED-2019-2497; Contract No .: 342PED/2020; Project title: Advanced theranostic strategy in atherosclerosis integrating pharmaco-epigenomic interventions and biomimetic microbubbles as ultrasound-mediated targeted drug delivery systems
• ECHOES PN-III-P2-2.1-PED-2016-1308. No. contract : 137PED/2017. Project title: Nanotechnology-based non-learning method for molecular imaging of oxidative stress in cardiovascular disease
• DIAVAN - PN-III-P1-1.1-PD-2019-0247 – Project title : Preclinical evaluation of newly designed vanadium compounds for diabetes therapy - 2020-2022
• BIOPRINT PN-III-P1-1.1-PD-2016-1660, Contract No. 19 / 2018. Project title: Tissue engineering of blood vessels using three-dimensional bioprinting of endothelial and smooth muscle progenitor cells
• Co-SuStain PN-III-P2-2.1-PED-2016-1881 Contract No .: 251PED/2017: Consolidating the Subcutaneous Transplantation of Mesenchymal Stem Cells as a Warranted Therapy for Myocardial Infarction
• ComTISM: Ischemic tissue engineering by combinatorial transplantation : assembling the pieces that induce both graft survival and host tissue repair
• FIBROSTEM PN-III-P1-1.1-PD-2019-1234. Contract No .: 160 of 25/08/2020 . Project title : The role of interaction between stromal cells mesenchymal and fibroblasts in the modulation of cardiac fibrosis via matrix metalloproteinase CD147
• APGEN: Genetically engineered apolipoproteins immobilized on nanoparticles: a Molecular Trojan horse targeting atherosclerotic plaque
• NICAD: New insights in platelet-endothelial progenitor cell interplay in atherosclerotic disease
• MISTAD: Microparticles as intracellular delivery strategies for microRNAs and potential therapies for atherosclerotic vascular disease
• AterTE: Combined hormonal treatment-induced gene transactivation of anti-atherosclerotic proteins as an innovative therapeutic approach for atherosclerosis
• NANORAGE: Endothelial-targeted nanotherapy designed to silence receptor for advanced glycation end products (RAGE) and reduce inflammation in atherosclerosis
• MECLIPINSMETAB: Molecular mechanisms of hyperlipidemia-induced insulin resistance; metabolic connections between the intestine, liver steatosis and atherosclerosis
• MIRDIATRIX: MicroRNA signature of vascular cells cross-talk relevant for the atherosclerotic plaque rupture in patients with type II diabetes
• THERAMIR: Assessment of molecular strategies to improve atherogenic dyslipidemia by modulating the microRNAs expression
• [GENITIR]: Molecular markers for improvement of the diagnostic and follow-up protocols of differentiated thyroid cancer for a better treatment outcome, prognosis and quality of life
• [S100MAP]: Role of S100A4 and MAP4K4 in pancreatic ductal adenocarcinoma progression
• [FABIO3D]: Fabrication of osteoinductive orthopedic implants with gradual 3D hierarchical structure
• [PCCA-1-CONTRACT 79/2012]:Preclinical model of cell therapy employing protein tyrosine phosphatase-microRNA interplay to optimize neovascularization, acronym “THERION”, PNCDI-II-Partnership-2012-2015, Project obtained by Dr. Marilena Plesu (Lupu) as Principal Investigator, and transferred/currently coordinated by Dr. Alexandrina Burlacu
• [BIOMARCAD]: Project title: „New predictive biomarkers for the evolution of the stable and unstable coronary artery disease identified by lipidomic, proteomic and molecular biology technologies” (BIOMARCAD), PROJECT ID: PCCA 127/2012 - 2015, Coordinator: Anca V. Sima
• [PN-II-ID-PCE-2011-3-0548]:Molecular regulation of oxidative stress in atherosclerosis: development of an innovative nanocarrier-based antioxidant therapy. Coordinator: Maya Simionescu
• [PN-II-ID-PCE-2011-3-0591]: New anti-atherosclerotic cellular therapeutic procedures based on apolipoprotein E. Coordinator:Anca Gafencu
• [CNCSIS PNII-TE 26/2011-2014]: Investigation of molecular mechanisms of endothelin system in diabetes; development of new pharmacological strategies to improve vascular function. Coordinator: Simona-Adriana Manea
• [REFINATER]: Molecules and mechanisms involved in cytokine and chemokine-dependent vascular inflammation as targets for novel nanotherapeutic strategies, PN-II-ID-PCE-2011-2014, Coordinator: Ileana Manduteanu
• [ATHEROSCLEROSIS]: CNCS – UEFISCDI Project ID PNII-CT-ERC-2012–1- grant no.6/2012-2014. Grant of the Romanian National Authority for Scientific Research, Coordinator: Adriana Georgescu .
• [RECORD]: Molecular mechanisms of human umbilical cord-derived stem cells integration and vasculogenesis within the cardiac tissue; implications for cardiovascular regeneration, acronym “RE-CORD”, CNCSIS PNCDI-II-TE-2010-2013, Principal Investigator: Dr. Marilena Plesu (Lupu)
• [CNCSIS PNII-TE 105/2010]: Development of new strategies to improve cell survival and differentiation of stem cells after transplantation into the ischemic myocardium. Coordinator: Alexandrina Burlacu
• [ CNCSIS PNII-TE 65/2010-2013 ]: New molecular pharmacology strategies for reducing oxidative and inflammatory stress in vascular wall cells in diabetes. CNCSIS PNII-TE 65/2010Coordinator: Adrian Manea
• [ PCCE 248 ]: New concepts and strategies for the development of knowledge of new biocompatible structures in bioengineering
• [ Update]: Project PNII_IDEI 1005/2009, Project title: Inflammation and oxidative stress in atherosclerosis : cellular and molecular mechanisms, identification and characterization of new dysfunctional artificial intelligence biomarkers Vascular coordinator: Adrian Mane
• Use of endothelial progenitor cells differentiated from human bone marrow and placenta in cellular therapy Use of endothelial progenitor cells differentiated from human bone marrow and placenta in cellular therapy Coordinator: Marilena Lupu [Prezentare Proiect] [Update]
• Comparative analysis of the molecular signals involved in the differentiation of mouse embryonic stem cells and multipotent adult progenitor cells - Coordinator: Alexandrina Burlacu [Information about Project] [Faza 1 - decembrie 2007] [Faza 2 - iunie 2008] [Faza 3 - ianuarie 2009 ] [Faza 4 - august 2009 ] [Prezentare.pps]
• Grant from Ministry of Education, Research and Youth, CNCSIS, National Program for Research-Development and Innovation 2 (PNCDI-2), Program Human Resources/ Research Projects for young PhD. Students- TD type: The studies of platelet dysfunction associated with vascular system changes in ageing and pathological conditions; Grant no 11/2.06.2008; Nicoleta Alexandru (2008-2009)
• 2007-2010 - PN II – IDEAS : Structural or vascular changes in the brain in hyperlipemia and aging , as risk factors for neurodegenerative diseases such as Alzheimer's. Project director: Elena Constantinescu
• In vitro manipulation of adult progenitor cells and stabilization of autologous cell transplantation efficiency in myocardial infarction treatment - Coordinator: Alexandrina Bachelor [ Project Presentation ]
• Cellular and molecular mechanisms involved in the development of atherosclerotic plaque . PN-II Ideas Program carried out by UEFISCSU - Coordinator: Felicia Antohe [ Project Presentation]
• The molecular interrelationship between chronic inflammation and accelerated atherosclerosis : role of recently discovered molecules, resistin , fractalkine , CXCL16; opportunities for new targeted therapies - Coordinator: Ileana Mânduțeanu [ Project Presentation ]
• Cryopreserved stem cell bank for autologous transplantation research SI - Coordinator: Horia Maniu [ Project Presentation ]
• Study of the cellular, molecular and genetic mechanisms by which dyslipidemia induces insulin resistance; identification of compounds probiotics activities and treatment methods - Coordinator: Anca Volumnia Sima Project Presentation
• The identification of human stem cells markers and mechanisms of in vitro differentiation for myocardial regeneration, Acronym: CARDIOSTEM, Coordinator: Maya Simionescu
• Vascular complications of arterioles in obese patients associated or not with type 2 diabetes; dysfunctions endothelial cells and insulin resistance - Coordinator: Adriana Georgescu [ IDEI Project Details ​]
• The ratio of circulating microparticles to endothelial cells progenitors , a new cellular marker of dysfunctions endothelial induction of association between hypertension and hypercholesterolemia; the anti- atherosclerotic effect of irbersartan - Coordinator: Adriana Georgescu [ PARTNERSHIP Project Details ​]
• The effect of elevated levels of membrane-released microparticles on peripheral vein function in patients with chronic venous insufficiency - Coordinator: Adriana Georgescu [ Project Presentation ​]
• Basic and clinical research on the altered cellular and molecular mechanisms and gene expression in cardiovascular disease and diabetes/obesity, disorders linked to the metabolic syndrome, Acronym: AMCADO, Coordinator: Maya Simionescu
• Genetics and endocrine-metabolic-cognitive changes in human aging, Acronym: GENAGE, ICBP partner, Coordinator: Constantina Heltianu
• In vitro differentiation of the adult progenitor cells and the assessment of the cell transplantation efficiency in myocardial repair as a function of the differentiation stage of grafted cells, Grant for Excellence Research Projects - Young Researchers, Director: Alexandrina Burlacu
• In vitro effect of the ischemic myocardium released factorsin the cardiomyocyte differentiation of adult stem cells, Research project for scientific research ; youth candidates for a doctor's degree, Director: Ana-Maria Rosca
• 2003-2005 - CERES : Studies on cerebral vascularization in the aging process . Project director: Elena Constantinescu
• eNOS transition analyzed by GFP. Project manager: Ciprian Neagoe. (Grant of the Romanian Academy, no. 152/2000)

ANSTI 1999-2001: Dynamics of endothelium-monocyte interactions and endothelial extracellular matrix in normal and pathological cases. Project director: Elena Constantinescu